Iridex SEC Filings

William M. Moore, a director of Iridex Corporation (IRIX), reported purchases of the company’s common stock on 08/18/2025. The filing shows he acquired 12,024 shares at a weighted average price of $1.1834 per share (prices ranged from $1.175 to $1.1899). After the purchases, Mr. Moore directly beneficially owned 200,674 shares. The filing also discloses indirect holdings of 69,300 shares held by his spouse and 30,026 shares held in two trusts where he and his spouse serve as trustees/tenants in common. The Form 4 was signed on behalf of Mr. Moore by an attorney-in-fact on 08/19/2025.

Iridex Corp (IRIX) insider purchase reported. Romeo R. Dizon, listed as Chief Financial Officer and reporting person, acquired a total of 1,500 shares on 08/18/2025 in two transactions: 460 shares at $1.19 and 1,040 shares at $1.1723. After these purchases he is shown as beneficially owning 40,745 shares.

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases of company common stock on 08/15/2025. He acquired 1,000 shares at $1.1799 per share and 500 shares at $1.15 per share, bringing his total reported beneficial ownership to 39,245 shares following the transactions. The Form 4 was signed on behalf of Mr. Dizon by an attorney-in-fact on 08/18/2025. No derivative transactions or other material changes were reported in this filing.

IRIDEX Corporation reported quarterly revenue of $13.6 million (up 7.4% year-over-year) and six-month revenue of $25.5 million (up 4.4%). Gross margin for the quarter was 34.5% versus 40.7% a year earlier, and six-month gross margin was 38.2%. The company recorded a net loss of $0.99 million for the quarter and $2.68 million for the six-month period. Cash and cash equivalents rose to $6.8 million and working capital was $13.2 million, supported by financing activity.

The company completed financings including issuance of 600,000 Series B preferred shares for $6.0 million and a $4.0 million convertible note; it also recognized a $1.3 million loss on extinguishment of a prior convertible note. Topcon remains a material related-party customer, representing ~32% of quarterly revenue and ~29% of accounts receivable. Inventories were $8.4 million and deferred revenue ended at $9.9 million.

IRIDEX Corporation disclosed a press release reporting its financial results for the second fiscal quarter ended June 28, 2025, and furnished that release as Exhibit 99.1 to this Form 8-K. The company specifies that the press release is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it is incorporated by reference only as expressly stated. The filing confirms the company’s common stock trades on the Nasdaq Capital Market under the symbol IRIX and is signed by Chief Executive Officer Patrick Mercer.

IRIDEX Corp (IRIX) Form 4: On 06/30/2025 President & CEO Patrick Mercer surrendered 4,243 common shares at $0.8819 under Transaction Code F. The shares were automatically withheld by the company to satisfy payroll-tax obligations tied to the net settlement of restricted stock units, so no open-market sale occurred.

After the withholding, Mercer still directly owns 415,857 IRIX shares, maintaining a significant equity stake. No derivative transactions were reported and there were no changes to his options or RSU schedule.

The disposition is valued at roughly $3.7 k, an amount that is immaterial relative to IRIDEX’s market capitalisation and Mercer's remaining holdings. As such, the filing carries limited market significance and is primarily an administrative compliance event.

This Form 4/A is an amendment to a previously filed Form 4 for Scott Shuda, a Director of Iridex Corp (IRIX), reporting a stock option grant on June 13, 2025. The original filing was made on June 17, 2025.

Key details of the transaction:

• Granted 53,000 stock options to purchase common stock
• Exercise price set at $0.94 per share
• Options expire on June 13, 2032
• Vesting occurs at earlier of: one-year anniversary of grant date or 2026 annual stockholder meeting

The options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Scott Shuda on June 24, 2025.

This Form 4/A filing amends a previously filed Form 4 dated June 17, 2025, reporting insider trading activity for Beverly A. Huss, a Director of Iridex Corp (IRIX). The amendment discloses a stock option grant that occurred on June 13, 2025.

Key details of the transaction:

• Granted 53,000 stock options to purchase common stock
• Exercise price set at $0.94 per share
• Options expire on June 13, 2032
• Vesting occurs at earlier of one-year anniversary or 2026 annual stockholder meeting

The stock options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Beverly Huss on June 24, 2025.